BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$58.01
0.05 (0.09%)
▲
5d:
+2.03%
30d:
-2.43%
90d:
+8.28%
BUY
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Feb 18, 2026
14d
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 1.0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 1.0% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$109.67
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$68.10
14.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $58.01, which is considered fair relative to its 30-day fair value range of $55.96 to $59.58. The stock's valuation (Forward PE: 11.1) is in line with its historical norms (10.8). At these levels, the market is pricing in 1.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $58.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $90.74 (+56.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $58.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $90.74 (+56.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$55.96 -
$59.58
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
73.3%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 56.6% below Wall St target ($90.74)
- NEUTRAL: Market pricing in 1.0% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$55.96 -
$59.58
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$55.28
Resistance Level
$58.50
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
11.11
Wall Street Target
$90.74
(+56.6%)
Revenue Growth (YoY)
4.1%
Earnings Growth (YoY)
124.3%
Profit Margin
16.8%
Valuation Premium vs History
+1.0% premium
PE vs Historical
11.1 vs 10.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$58.53
(+1%)
2-Year Target
$59.11
(+2%)
3-Year Target
$59.71
(+3%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$58.02
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 54.6%)
$392.46
(+577%)
Base:
(SPY PE: 11.1, Growth: 54.6%)
$195.58
(+238%)
Bear:
(PE: 9.4, Growth: 54.6%)
$166.24
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 21.02 | Current EPS (TTM): $2.69
Bull Case
$120.56
(+108%)
Analyst growth 93.9%, PE expands to 23.1
Base Case
$109.60
(+89%)
Market implied 93.9%, PE stable at 21.0
Bear Case
$38.45
(-34%)
Severe decline -20.0%, PE contracts to 17.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 03, 2026 10:06 AM ET
Data refreshes hourly during market hours. Next update: 11:06 AM
Data refreshes hourly during market hours. Next update: 11:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 62 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 54 HOLD |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
